Abstracts Archive - Page 1465 of 2425 - ACR Meeting Abstracts

Abstract Number: 709 • 2016 ACR/ARHP Annual Meeting
Development of a Novel Medication Adherence Prediction Model for Patients with Ankylosing Spondylitis Based on Results from a Global Clinical Study
Philip J Mease¹, Josef S. Smolen², Dafna D Gladman³, Joachim Sieper⁴, John Weinman⁵, Julia Sommer⁶, Pascal Nurwakagari⁷ and Maja Hojnik⁸, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medical University of Vienna, Vienna, Austria, ³University of Toronto, Toronto, ON, Canada, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵King's College, London, United Kingdom, ⁶GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁸AbbVie, Ljubljana, Slovenia
Background/Purpose: Adherence to systemic therapies, such as tumor necrosis factor inhibitors (TNFi’s), is affected by various factors and may be critical for optimal disease outcomes…
Abstract Number: 710 • 2016 ACR/ARHP Annual Meeting
Patient-Reported Quality of Life in Patients with Baseline Objective Signs of Inflammation and Active Nonradiographic Axial Spondyloarthritis Treated with Golimumab: Results of the Open-Label Extension of a Randomized, Double-Blind Study
Walter Maksymowych¹, Maxime Dougados², Joachim Sieper³, Jürgen Braun⁴, G Bergman⁵, Sean P. Curtis⁶, Anjela Tzontcheva⁶, George Philip⁶, Susan Huyck⁶ and Désirée van der Heijde⁷, ¹Medicine, University of Alberta,, Edmonton, AB, Canada, ²Paris-Descartes University, Paris, France, ³Rheumatology Department, Charité – University Medicine Berlin, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Merck & Co., Inc., Whitehouse Station, NJ, ⁶Merck & Co., Inc., Kenilworth, NJ, ⁷Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In an open-label extension (OLE) of a 16-week, randomized, double blind (DB), placebo (PBO)-controlled, phase 3 study (GO-AHEAD; NCT1453725) in patients with nonradiographic axial…
Abstract Number: 711 • 2016 ACR/ARHP Annual Meeting
The Diagnostic Value of the Symptom of Inflammatory Back Pain in the Rheumatology Setting
Denis Poddubnyy¹, Inge Spiller¹, Joachim Listing², Jürgen Braun³, Joachim Sieper¹ and Martin Rudwaleit⁴, ¹Charité Medical University, Berlin, Germany, ²German Rheumatism Research Center, Berlin, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany
Background/Purpose: Inflammatory back pain (IBP) as a symptom has been shown to perform effectively for selecting patients in primary care / orthopaedic settings for referral…
Abstract Number: 712 • 2016 ACR/ARHP Annual Meeting
Efficacy of Golimumab for Nonradiographic Axial Spondyloarthritis (nr-axSpA): Subgroup Analysis By Baseline MRI and C-Reactive Protein Status
Joachim Sieper¹, Désirée van der Heijde², Walter Maksymowych³, Jürgen Braun⁴, G Bergman⁵, Sean P. Curtis⁶, Anjela Tzontcheva⁶, George Philip⁶, Susan Huyck⁶ and Maxime Dougados⁷, ¹Rheumatology Department, Charité – University Medicine Berlin, Berlin, Germany, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Medicine, University of Alberta,, Edmonton, AB, Canada, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Merck & Co., Inc., Whitehouse Station, NJ, ⁶Merck & Co., Inc., Kenilworth, NJ, ⁷Paris-Descartes University, Paris, France
Background/Purpose: Efficacy of golimumab (GLM) for nr-axSpA was demonstrated in a randomized, double-blind (DB), placebo (PBO)-controlled, phase 3 study (GO-AHEAD; NCT01453725).1 In a subgroup analysis,…
Abstract Number: 713 • 2016 ACR/ARHP Annual Meeting
Predictors of Treatment Retention Among Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Treated with Remicade® (Infliximab) for Long-Term in Canadian Real-World
Michael Starr¹, Edward Keystone², Rafat Faraawi³, Louis Bessette⁴, Boulos Haraoui⁵, Wojciech Olszynski⁶, John Kelsall⁷, Raman Joshi⁸, Andrew Chow⁹, Algis Jovaisas¹⁰, J Carter Thorne¹¹, Emmanouil Rampakakis¹², Eliofotisti Psaradellis¹³, Marilise Marrache¹⁴, Brendan Osborne¹⁵, Karina Maslova¹⁶, Francois Nantel¹⁷, Allen J Lehman¹⁶ and Cathy Tkaczyk¹⁵, ¹Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, ²Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³McMaster University, Hamilton, ON, Canada, ⁴Rheumatology, CHUL de Quebec, Quebec, QC, Canada, ⁵Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada, ⁶103 Midtown Professional Center, Rheumatology Associates of Saskatoon, Saskatoon, SK, Canada, ⁷Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁸William Osler Health Centre-Brampton Civic Hospital, Brampton, ON, Canada, ⁹Credit Valley Rheumatology, Mississauga, ON, Canada, ¹⁰Capital North Therapeutics & Research, Ottawa, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²JSS Medical Research, St-Laurent, QC, Canada, ¹³JSS Medical Research, Montreal, QC, Canada, ¹⁴Medical Affairs, Janssen Inc, Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁶Janssen Inc., Toronto, ON, Canada, ¹⁷19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Remission has become a target to achieve in rheumatic diseases and it also could be linked to treatment retention. The aim of this analysis…
Abstract Number: 714 • 2016 ACR/ARHP Annual Meeting
Functional Relevance of Structural Damage in the Sacroiliac Joints in Patients with Axial Spondyloarthritis – Results from the German Spondyloarthritis Inception Cohort
Mikhail Protopopov¹, Hildrun Haibel¹, Jürgen Braun², Martin Rudwaleit³, Joachim Sieper¹ and Denis Poddubnyy¹, ¹Charité Medical University, Berlin, Germany, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany
Background/Purpose: To analyze the association between the presence of structural damage in the sacroiliac joints and physical function / spinal mobility in patients with axial…
Abstract Number: 715 • 2016 ACR/ARHP Annual Meeting
Are Patients with Ankylosing Spondylitis Willing to Pay for Treatment with Infliximab?
Casper Webers^1,2, Ivette Essers^1,2, Astrid van Tubergen^1,2, Jürgen Braun³, Frank Heldmann⁴, Xenofon Baraliakos⁵ and Annelies Boonen^2,6, ¹Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Zeisigwaldkliniken Bethanien, Chemnitz, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁶Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: In view of the continuous pressure of biologicals on healthcare budgets, it is essential to assess the value of biologicals for patients from different…
Abstract Number: 716 • 2016 ACR/ARHP Annual Meeting
Radiographic Progression and Changes in Inflammation and Structural Damage on Serial MRI Examinations over 5 Years in Patients with Ankylosing Spondylitis Treated with TNF-Alpha Inhibitors
Susanne Juhl Pedersen¹, Ulrich Weber², Roula Said Nahal³, Inge Juul Sorensen¹, Anne Gitte Loft⁴, Niels Tvede¹, Gina Kollerup¹, Lars Juul¹, Gorm Thamsborg¹, Ole Rintek Madsen¹, Jakob M. Møller⁵, Lone Balding⁶, Anne Grethe Jurik⁷ and Mikkel Østergaard⁸, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ²Department of Research, King Christian 10th Hospital for Rheumatic Diseases, Graasten, Denmark, ³Ambroise Paré Hospital, Boulogne-Billancourt, France, ⁴Departments of Rheumatology at Vejle and Aarhus Hospitals, Vejle and Aarhus, Denmark, ⁵Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark, ⁶Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Copenhagen, Denmark, ⁷Dept. of Radiology, Aarhus University Hospital, Aarhus, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark
Background/Purpose: Only few studies have investigated long-term radiographic progression in the spine of patients with ankylosing spondylitis (AS). Moreover, no studies have reported changes in…
Abstract Number: 717 • 2016 ACR/ARHP Annual Meeting
NSAID Use and Functional Impairment in Ankylosing Spondylitis
Mark Hwang¹, Seth Eisen¹, MinJae Lee², Michael Ward³, Lianne S. Gensler⁴, Prabha Ranganathan⁵, Johnathan Jia⁶, Amirali Tahanan², Matthew A. Brown⁷, Mohammad H. Rahbar², Michael Weisman⁸ and John D. Reveille⁹, ¹Internal Medicine-Rheumatology, Washington University in Saint Louis, School of Medicine, Saint Louis, MO, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ³NIH/NIAMS, Bethesda, MD, ⁴Medicine/Rheumatology, UCSF, San Francisco, CA, ⁵Washington University in Saint Louis, School of Medicine, Saint Louis, MO, ⁶University of Texas-McGovern Medical School, Houston, TX, ⁷The University of Queensland Diamantina Institute, Brisbane, Australia, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease with significant burden to patients and society. NSAIDs are the first line pharmacologic therapy in…
Abstract Number: 718 • 2016 ACR/ARHP Annual Meeting
Radiographic Progression of Hip Arthritis in Patients with Ankylosing Spondylitis Treated with TNF Inhibitors
Maria Konsta¹, Michael Nurmohamed², J.C. van Denderen³, Ingrid Visman⁴ and I.E. Van der Horst - Bruinsma⁵, ¹Amsterdam Rheumatology and Immunology Center,VUmc and Reade, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ³Center for Rheumatology and Rehabilitation, Jan van Breemen Institute, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and Immunology Center, VUmc and Reade, Amsterdam, Netherlands, ⁵GENRA Consortium, Amsterdam, Netherlands
Background/Purpose: Although current evidence suggests that anti-TNF treatment may not inhibit spinal radiographic progression, its effect on hip involvement in AS is not known. The…
Abstract Number: 719 • 2016 ACR/ARHP Annual Meeting
Prevalence and Incidence of Comorbidities in Patients with Ankylosing Spondylitis Versus General Population
Jessica Walsh¹, Xue Song², Gilwan Kim² and Jina Park³, ¹University of Utah School of Medicine, Salt Lake City, UT, ²Truven Health Analytics, Cambridge, MA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Comorbidities associated with ankylosing spondylitis (AS) have been inadequately studied in American populations. This study used a large US national claims database to…
Abstract Number: 720 • 2016 ACR/ARHP Annual Meeting
Impact of HLA-B27 on Patient Profile and Treatment Response in As Patients Treated with Anti-TNF in Canadian Real-World
Isabelle Fortin¹, Maqbool Sheriff², Proton Rahman³, Michael Starr⁴, Wojciech Olszynski⁵, Sanjay Dixit⁶, Viktoria Pavlova⁷, Derek Haaland⁸, Emmanouil Rampakakis⁹, Eliofotisti Psaradellis¹⁰, Brendan Osborne¹¹, Karina Maslova¹², Allen J Lehman¹², Francois Nantel¹³ and Cathy Tkaczyk¹¹, ¹Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, ²Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ³Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ⁴Rheumatology, Mcgill University, Pointe-Claire,, QC, Canada, ⁵103 Midtown Professional Center, Rheumatology Associates of Saskatoon, Saskatoon, SK, Canada, ⁶Rheumatology, McMaster University Hamilton, Burlington, ON, Canada, ⁷Ancaster Medical Centre, Ancaster, ON, Canada, ⁸Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ⁹JSS Medical Research, St-Laurent, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The human leukocyte antigen (HLA)-B27 allele is one of the strongest known genetic factors associated with the development of ankylosing spondylitis, however, previous studies…
Abstract Number: 721 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Switching from Originator to CT-P13 Infliximab Biosimilar in Patients Affected By Spondyloarthritis. a 6-Month Observational Study
Alberto Batticciotto^1,2, Marco Antivalle², Francesca Li Gobbi³, Simone Parisi⁴, Rossella Talotta², Valentina Varisco², Maurizio Benucci³, Enrico Fusaro⁴ and Piercarlo Sarzi-Puttini¹, ¹Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ²Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, ³Rheumatology Unit, Ospedale S. Giovanni di Dio, Florence, Florence, Italy, ⁴Department of Rheumatology, University Hospital Città Della Salute e della Scienza di Torino, Turin, Italy
Background/Purpose: Biosimilar infliximab (INX) was recently approved by the European Medicine Agency based on comparable pharmacokinetics, safety and efficacy profile to innovator INX for the…
Abstract Number: 722 • 2016 ACR/ARHP Annual Meeting
Impact of Aerobic Fitness on Axial Spondyloarthritis Activity: Systematic Review and Meta-Analysis of Controlled Studies
Frank Verhoeven¹, Xavier Guillot², Clément Prati³, Nicolas Tordi⁴, Céline Demougeot¹ and Daniel Wendling⁵, ¹EA 4267 FDE, FHU INCREASE, Université de Bourgogne Franche-Comté, Besançon, France, ²EA 4267 FDE, FHU INCREASE, Université de Bourgogne FrancheComté, Besançon, France, ³FDE EA4267, FHU INCREASE, Bourgogne Franche-Comté University, Besançon, France, ⁴EA 4267 FDE, FHU INCREASE,, Bourgogne Franche-Comté University, Besançon, France, ⁵Service de Rhumatologie, CHU Jean Minjoz, Besancon, France
Background/Purpose: The current ASAS recommendations for the management of the ankylosing spondylitis suggest, beside pharmacological therapy, a significant part of physical therapy with supervised exercises.…
Abstract Number: 723 • 2016 ACR/ARHP Annual Meeting
Hip Disease Treatment and Progression in Ankylosing Spondylitis
Daphne Scaramangas-Plumley¹, MinJae Lee², Mohammad H. Rahbar², Lianne S. Gensler³, John D. Reveille⁴ and Michael Weisman¹, ¹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas-McGovern Medical School, Houston, TX, ³Medicine/Rheumatology, UCSF, San Francisco, CA, ⁴Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Methods: We included 613 AS patients meeting the modified New York criteria and had at least 2 sets of hip radiographs. Using the Bath Ankylosing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].